A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions

Alzheimer's Disease

Interventions

DRUG

MK-1708

Oral administration

DRUG

Itraconazole

Oral administration

Trial Locations (1)

QPS-MRA, LLC ( Site 0001), South Miami

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06586606 - A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) | Biotech Hunter | Biotech Hunter